Thomas Strüngmann Net Worth

Thomas Strüngmann has an estimated net worth of $11 billion, according to Forbes Real-Time Billionaires, Thomas Strüngmann profile (figures as of October 20, 2026). That is up from $4.4 billion in 2019.

Thomas Strüngmann is a German businessman and investor best known for building wealth in pharmaceuticals and biotech with his twin brother, Andreas. After earning a business degree from the University of Augsburg, he worked as a marketing manager at Schering-Plough. A big turning point came in 1986, when the brothers cofounded generic drugmaker Hexal. That company became the base for much of his later investing across healthcare, life sciences, biotech, and pharma.

His profile grew again through early backing of BioNTech, the German company that later partnered with Pfizer to make a vaccine for Covid-19. The brothers also invest through Santo Holding, based in Zug, Switzerland, and operate through the family office Athos Service. Beyond drug companies, they made deals in banking and medical technology, including Südwestbank and Siemens Audiology Solutions. In 2008, they also established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.

How Thomas Strüngmann built his fortune

The core of Thomas Strüngmann's wealth comes from pharmaceuticals. In 1986, he and Andreas cofounded Hexal, a generic drugmaker that became their first major business success. They sold Hexal to Novartis in 2005 for some $7 billion, and the Wikipedia background also notes a $6.7 billion sale figure. After that deal, Thomas joined Novartis subsidiary Sandoz in a senior regional role covering Germany, the Americas, and the Middle East.

He later put more capital into healthcare investing. Through Santo Holding, the brothers backed biotech, pharma, life sciences, and healthcare companies. One of their most important bets was BioNTech, where they were early backers before the company partnered with Pfizer on a Covid-19 vaccine. Their deal activity also reached beyond drug development. In 2004, Santo Holding acquired 89.6 percent of Südwestbank, and in 2014 Santo Holding and EQT AB bought Siemens Audiology Solutions for €2.2 billion.

Forbes net worth and key money moments

Forbes has tracked large swings in Thomas Strüngmann's fortune over time. Its World's Billionaires List estimated his wealth at $4.4 billion in 2019, then $9.6 billion in 2020 and $11 billion in 2021. Forbes later put him at $11.9 billion in 2022, before trimming the estimate to $11.5 billion in 2023 and $9.8 billion in 2024. Those shifts fit a fortune tied closely to biotech and pharmaceutical holdings.

More recently, Forbes valued him at $11.3 billion in 2025 and $12 billion in 2026 on its annual list. Forbes' real-time billionaires tracker later showed $11 billion as of October 20, 2026. The broad picture is consistent across the record of his career: he built wealth first through Hexal, then kept expanding it through healthcare investing, including BioNTech and other life sciences holdings managed with his brother through Santo Holding and Athos Service.